Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 246

1.

Prospective assessment of patient-reported outcomes and estradiol and drug concentrations in patients experiencing toxicity from adjuvant aromatase inhibitors.

Kadakia KC, Kidwell KM, Seewald NJ, Snyder CF, Storniolo AM, Otte JL, Flockhart DA, Hayes DF, Stearns V, Henry NL.

Breast Cancer Res Treat. 2017 Jul;164(2):411-419. doi: 10.1007/s10549-017-4260-2. Epub 2017 Apr 27.

2.

Influence of Oral Progesterone Administration on Drug-Induced QT Interval Lengthening: A Randomized, Double-Blind, Placebo-Controlled Crossover Study.

Tisdale JE, Jaynes HA, Overholser BR, Sowinski KM, Flockhart DA, Kovacs RJ.

JACC Clin Electrophysiol. 2016 Dec;2(7):765-774. doi: 10.1016/j.jacep.2016.02.015.

3.

Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.

Robarge JD, Desta Z, Nguyen AT, Li L, Hertz D, Rae JM, Hayes DF, Storniolo AM, Stearns V, Flockhart DA, Skaar TC, Henry NL.

Breast Cancer Res Treat. 2017 Feb;161(3):453-461. doi: 10.1007/s10549-016-4077-4. Epub 2016 Dec 9.

4.

A new Suzuki synthesis of triphenylethylenes that inhibit aromatase and bind to estrogen receptors α and β.

Zhao LM, Jin HS, Liu J, Skaar TC, Ipe J, Lv W, Flockhart DA, Cushman M.

Bioorg Med Chem. 2016 Nov 1;24(21):5400-5409. doi: 10.1016/j.bmc.2016.08.064. Epub 2016 Aug 31.

5.

Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.

Desta Z, Metzger IF, Thong N, Lu JB, Callaghan JT, Skaar TC, Flockhart DA, Galinsky RE.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6813-6822. doi: 10.1128/AAC.01000-16. Print 2016 Nov.

6.

Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.

Hertz DL, Kidwell KM, Seewald NJ, Gersch CL, Desta Z, Flockhart DA, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM.

Pharmacogenomics J. 2017 Dec;17(6):521-527. doi: 10.1038/tpj.2016.60. Epub 2016 Aug 23.

7.

Simultaneous administration of high-dose atorvastatin and clopidogrel does not interfere with platelet inhibition during percutaneous coronary intervention.

Kreutz RP, Breall JA, Sinha A, von der Lohe E, Kovacs RJ, Flockhart DA.

Clin Pharmacol. 2016 Jun 3;8:45-50. doi: 10.2147/CPAA.S98790. eCollection 2016.

8.

Comparative risk of severe hypoglycemia among concomitant users of thiazolidinedione antidiabetic agents and antihyperlipidemics.

Leonard CE, Han X, Bilker WB, Flory JH, Brensinger CM, Flockhart DA, Gagne JJ, Cardillo S, Hennessy S.

Diabetes Res Clin Pract. 2016 May;115:60-7. doi: 10.1016/j.diabres.2016.03.006. Epub 2016 Mar 14.

9.

Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity.

Hertz DL, Deal A, Ibrahim JG, Walko CM, Weck KE, Anderson S, Magrinat G, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schwartz G, Graham M, Peppercorn JM, Jones DR, Desta Z, Flockhart DA, Evans JP, McLeod HL, Carey LA, Irvin WJ Jr.

Oncologist. 2016 Jul;21(7):795-803. doi: 10.1634/theoncologist.2015-0480. Epub 2016 May 25.

10.

Aromatase inhibitors augment nociceptive behaviors in rats and enhance the excitability of sensory neurons.

Robarge JD, Duarte DB, Shariati B, Wang R, Flockhart DA, Vasko MR.

Exp Neurol. 2016 Jul;281:53-65. doi: 10.1016/j.expneurol.2016.04.006. Epub 2016 Apr 9.

11.

Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers.

Cho DY, Shen JH, Lemler SM, Skaar TC, Li L, Blievernicht J, Zanger UM, Kim KB, Shin JG, Flockhart DA, Desta Z.

Drug Metab Pharmacokinet. 2016 Apr;31(2):107-16. doi: 10.1016/j.dmpk.2015.07.002. Epub 2015 Jul 29.

12.

Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer.

Kadakia KC, Snyder CF, Kidwell KM, Seewald NJ, Flockhart DA, Skaar TC, Desta Z, Rae JM, Otte JL, Carpenter JS, Storniolo AM, Hayes DF, Stearns V, Henry NL.

Oncologist. 2016 May;21(5):539-46. doi: 10.1634/theoncologist.2015-0349. Epub 2016 Mar 23.

13.

Implementation of a pharmacogenomics consult service to support the INGENIOUS trial.

Eadon MT, Desta Z, Levy KD, Decker BS, Pierson RC, Pratt VM, Callaghan JT, Rosenman MB, Carpenter JS, Holmes AM, McDonald CA, Benson EA, Patil AS, Vuppalanchi R, Gufford BT, Dave N, Robarge JD, Hyder MA, Haas DM, Kreutz RP, Dexter PR, Skaar TC, Flockhart DA.

Clin Pharmacol Ther. 2016 Jul;100(1):63-6. doi: 10.1002/cpt.347. Epub 2016 Mar 31. Review.

14.

Pharmacogenomically actionable medications in a safety net health care system.

Carpenter JS, Rosenman MB, Knisely MR, Decker BS, Levy KD, Flockhart DA.

SAGE Open Med. 2016 Jan 7;4:2050312115624333. doi: 10.1177/2050312115624333. eCollection 2016.

15.

The IGNITE network: a model for genomic medicine implementation and research.

Weitzel KW, Alexander M, Bernhardt BA, Calman N, Carey DJ, Cavallari LH, Field JR, Hauser D, Junkins HA, Levin PA, Levy K, Madden EB, Manolio TA, Odgis J, Orlando LA, Pyeritz R, Wu RR, Shuldiner AR, Bottinger EP, Denny JC, Dexter PR, Flockhart DA, Horowitz CR, Johnson JA, Kimmel SE, Levy MA, Pollin TI, Ginsburg GS; IGNITE Network.

BMC Med Genomics. 2016 Jan 5;9:1. doi: 10.1186/s12920-015-0162-5.

16.

Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors.

Lv W, Liu J, Skaar TC, O'Neill E, Yu G, Flockhart DA, Cushman M.

J Med Chem. 2016 Jan 14;59(1):157-70. doi: 10.1021/acs.jmedchem.5b01677. Epub 2015 Dec 24.

17.

Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics.

Leonard CE, Bilker WB, Brensinger CM, Han X, Flory JH, Flockhart DA, Gagne JJ, Cardillo S, Hennessy S.

Clin Pharmacol Ther. 2016 May;99(5):538-47. doi: 10.1002/cpt.297. Epub 2016 Jan 17.

18.

Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.

Oesterreich S, Henry NL, Kidwell KM, Van Poznak CH, Skaar TC, Dantzer J, Li L, Hangartner TN, Peacock M, Nguyen AT, Rae JM, Desta Z, Philips S, Storniolo AM, Stearns V, Hayes DF, Flockhart DA.

Breast Cancer Res Treat. 2015 Nov;154(2):263-73. doi: 10.1007/s10549-015-3608-8. Epub 2015 Nov 4.

19.

Steroid Pathway Genes and Neonatal Respiratory Distress After Betamethasone Use in Anticipated Preterm Birth.

Haas DM, Lai D, Sharma S, Then J, Kho A, Flockhart DA, Tantisira K, Foroud T.

Reprod Sci. 2016 May;23(5):680-6. doi: 10.1177/1933719115612129. Epub 2015 Oct 27.

20.

Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy.

Santa-Maria CA, Blackford A, Nguyen AT, Skaar TC, Philips S, Oesterreich S, Rae JM, Desta Z, Robarge J, Henry NL, Storniolo AM, Hayes DF, Blumenthal RS, Ouyang P, Post WS, Flockhart DA, Stearns V; Consortium on Breast Cancer Pharmacogenomics (COBRA).

Clin Cancer Res. 2016 Mar 15;22(6):1395-402. doi: 10.1158/1078-0432.CCR-15-1213. Epub 2015 Oct 13.

21.

Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199.

Schneider BP, Li L, Radovich M, Shen F, Miller KD, Flockhart DA, Jiang G, Vance G, Gardner L, Vatta M, Bai S, Lai D, Koller D, Zhao F, O'Neill A, Smith ML, Railey E, White C, Partridge A, Sparano J, Davidson NE, Foroud T, Sledge GW Jr.

Clin Cancer Res. 2015 Nov 15;21(22):5082-5091. doi: 10.1158/1078-0432.CCR-15-0586. Epub 2015 Jul 2.

22.

Cypiripi: exact genotyping of CYP2D6 using high-throughput sequencing data.

Numanagić I, Malikić S, Pratt VM, Skaar TC, Flockhart DA, Sahinalp SC.

Bioinformatics. 2015 Jun 15;31(12):i27-34. doi: 10.1093/bioinformatics/btv232.

23.

FDA's draft guidance on laboratory-developed tests increases clinical and economic risk to adoption of pharmacogenetic testing.

Levy KD, Pratt VM, Skaar TC, Vance GH, Flockhart DA.

J Clin Pharmacol. 2015 Jul;55(7):725-7. doi: 10.1002/jcph.492. No abstract available.

24.

Identification and Mechanistic Investigation of Drug-Drug Interactions Associated With Myopathy: A Translational Approach.

Han X, Quinney SK, Wang Z, Zhang P, Duke J, Desta Z, Elmendorf JS, Flockhart DA, Li L.

Clin Pharmacol Ther. 2015 Sep;98(3):321-7. doi: 10.1002/cpt.150.

25.

In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles.

Hertz DL, Snavely AC, McLeod HL, Walko CM, Ibrahim JG, Anderson S, Weck KE, Magrinat G, Olajide O, Moore S, Raab R, Carrizosa DR, Corso S, Schwartz G, Peppercorn JM, Evans JP, Jones DR, Desta Z, Flockhart DA, Carey LA, Irvin WJ Jr.

Br J Clin Pharmacol. 2015 Nov;80(5):1122-30. doi: 10.1111/bcp.12665. Epub 2015 Aug 2.

26.

Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities.

Lv W, Liu J, Skaar TC, Flockhart DA, Cushman M.

J Med Chem. 2015 Mar 26;58(6):2623-48. doi: 10.1021/jm501218e. Epub 2015 Mar 9.

27.

Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors.

Leonard CE, Bilker WB, Brensinger CM, Flockhart DA, Freeman CP, Kasner SE, Kimmel SE, Hennessy S.

Stroke. 2015 Mar;46(3):722-31. doi: 10.1161/STROKEAHA.114.006866. Epub 2015 Feb 5.

28.

Report of new haplotype for ABCC2 gene: rs17222723 and rs8187718 in cis.

Pratt VM, Beyer BN, Koller DL, Skaar TC, Flockhart DA, Levy KD, Vance GH.

J Mol Diagn. 2015 Mar;17(2):201-5. doi: 10.1016/j.jmoldx.2014.11.005. Epub 2014 Dec 29.

29.

Substantial effect of efavirenz monotherapy on bilirubin levels in healthy volunteers.

Metzger IF, Quigg TC, Epstein N, Aregbe AO, Thong N, Callaghan JT, Flockhart DA, Nguyen AT, Stevens CK, Gupta SK, Desta Z.

Curr Ther Res Clin Exp. 2014 Sep 27;76:64-9. doi: 10.1016/j.curtheres.2014.05.002. eCollection 2014 Dec.

30.

Is personalized medicine achievable in obstetrics?

Quinney SK, Patil AS, Flockhart DA.

Semin Perinatol. 2014 Dec;38(8):534-40. doi: 10.1053/j.semperi.2014.08.017. Epub 2014 Oct 3. Review.

31.

Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole.

Ingle JN, Kalari KR, Buzdar AU, Robson ME, Goetz MP, Desta Z, Barman P, Dudenkov TT, Northfelt DW, Perez EA, Flockhart DA, Williard CV, Wang L, Weinshilboum RM.

Steroids. 2015 Jul;99(Pt A):32-8. doi: 10.1016/j.steroids.2014.08.007. Epub 2014 Aug 24.

32.

Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100.

Schneider BP, Li L, Shen F, Miller KD, Radovich M, O'Neill A, Gray RJ, Lane D, Flockhart DA, Jiang G, Wang Z, Lai D, Koller D, Pratt JH, Dang CT, Northfelt D, Perez EA, Shenkier T, Cobleigh M, Smith ML, Railey E, Partridge A, Gralow J, Sparano J, Davidson NE, Foroud T, Sledge GW.

Br J Cancer. 2014 Sep 9;111(6):1241-8. doi: 10.1038/bjc.2014.430. Epub 2014 Aug 12.

33.

Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes.

Maximov PY, McDaniel RE, Fernandes DJ, Korostyshevskiy VR, Bhatta P, Mürdter TE, Flockhart DA, Jordan VC.

Br J Pharmacol. 2014 Dec;171(24):5624-35. doi: 10.1111/bph.12864.

34.

Platelet factor XIIIa release during platelet aggregation and plasma clot strength measured by thrombelastography in patients with coronary artery disease treated with clopidogrel.

Kreutz RP, Owens J, Lu D, Nystrom P, Jin Y, Kreutz Y, Desta Z, Flockhart DA.

Platelets. 2015;26(4):358-63. doi: 10.3109/09537104.2014.916793. Epub 2014 May 15.

35.

Prerequisites to implementing a pharmacogenomics program in a large health-care system.

Levy KD, Decker BS, Carpenter JS, Flockhart DA, Dexter PR, Desta Z, Skaar TC.

Clin Pharmacol Ther. 2014 Sep;96(3):307-9. doi: 10.1038/clpt.2014.101. Epub 2014 May 7.

36.

Patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor therapy.

Kidwell KM, Harte SE, Hayes DF, Storniolo AM, Carpenter J, Flockhart DA, Stearns V, Clauw DJ, Williams DA, Henry NL.

Cancer. 2014 Aug 15;120(16):2403-11. doi: 10.1002/cncr.28756. Epub 2014 May 6.

37.

Editors' report, November 2013.

Somogyi AA, Lewis LD, Cohen AF, Flockhart DA, Ferro A, Loke YK, Ritter JM.

Br J Clin Pharmacol. 2014 Mar;77(3):401-2. doi: 10.1111/bcp.12317. No abstract available.

38.

Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins.

Schelleman H, Han X, Brensinger CM, Quinney SK, Bilker WB, Flockhart DA, Li L, Hennessy S.

Br J Clin Pharmacol. 2014 Sep;78(3):639-48. doi: 10.1111/bcp.12353.

39.

Factor XIII Val34Leu polymorphism and recurrent myocardial infarction in patients with coronary artery disease.

Kreutz RP, Bitar A, Owens J, Desta Z, Breall JA, von der Lohe E, Sinha A, Vatta M, Nystrom P, Jin Y, Flockhart DA.

J Thromb Thrombolysis. 2014 Oct;38(3):380-7. doi: 10.1007/s11239-014-1059-4.

40.

Personal DNA donation to energize genomic medicine.

Lu WJ, Flockhart DA.

Clin Pharmacol Ther. 2014 Feb;95(2):129-31. doi: 10.1038/clpt.2013.131.

PMID:
24448457
41.

PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics.

Lowenberg D, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE.

Pharmacogenet Genomics. 2014 Feb;24(2):133-8. doi: 10.1097/FPC.0000000000000019. No abstract available.

42.

Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response.

Kreutz RP, Owens J, Jin Y, Nystrom P, Desta Z, Kreutz Y, Breall JA, Li L, Chiang C, Kovacs RJ, Flockhart DA.

Clin Pharmacol. 2013 Dec 9;5:185-92. doi: 10.2147/CPAA.S53151. eCollection 2013.

43.

Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects.

Henry NL, Chan HP, Dantzer J, Goswami CP, Li L, Skaar TC, Rae JM, Desta Z, Khouri N, Pinsky R, Oesterreich S, Zhou C, Hadjiiski L, Philips S, Robarge J, Nguyen AT, Storniolo AM, Flockhart DA, Hayes DF, Helvie MA, Stearns V.

Br J Cancer. 2013 Oct 29;109(9):2331-9. doi: 10.1038/bjc.2013.587. Epub 2013 Oct 1.

44.

CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations.

Province MA, Goetz MP, Brauch H, Flockhart DA, Hebert JM, Whaley R, Suman VJ, Schroth W, Winter S, Zembutsu H, Mushiroda T, Newman WG, Lee MT, Ambrosone CB, Beckmann MW, Choi JY, Dieudonné AS, Fasching PA, Ferraldeschi R, Gong L, Haschke-Becher E, Howell A, Jordan LB, Hamann U, Kiyotani K, Krippl P, Lambrechts D, Latif A, Langsenlehner U, Lorizio W, Neven P, Nguyen AT, Park BW, Purdie CA, Quinlan P, Renner W, Schmidt M, Schwab M, Shin JG, Stingl JC, Wegman P, Wingren S, Wu AH, Ziv E, Zirpoli G, Thompson AM, Jordan VC, Nakamura Y, Altman RB, Ames MM, Weinshilboum RM, Eichelbaum M, Ingle JN, Klein TE; International Tamoxifen Pharmacogenomics Consortium.

Clin Pharmacol Ther. 2014 Feb;95(2):216-27. doi: 10.1038/clpt.2013.186. Epub 2013 Sep 23.

45.

PharmGKB summary: tamoxifen pathway, pharmacokinetics.

Klein DJ, Thorn CF, Desta Z, Flockhart DA, Altman RB, Klein TE.

Pharmacogenet Genomics. 2013 Nov;23(11):643-7. doi: 10.1097/FPC.0b013e3283656bc1. Review. No abstract available.

46.

Regulation of microRNA expression by rifampin in human hepatocytes.

Ramamoorthy A, Liu Y, Philips S, Desta Z, Lin H, Goswami C, Gaedigk A, Li L, Flockhart DA, Skaar TC.

Drug Metab Dispos. 2013 Oct;41(10):1763-8. doi: 10.1124/dmd.113.052886. Epub 2013 Aug 9.

47.

Inhibition of cytochrome p450 enzymes by the e- and z-isomers of norendoxifen.

Liu J, Flockhart PJ, Lu D, Lv W, Lu WJ, Han X, Cushman M, Flockhart DA.

Drug Metab Dispos. 2013 Sep;41(9):1715-20. doi: 10.1124/dmd.113.052506. Epub 2013 Jul 3.

48.

Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention.

Ingle JN, Liu M, Wickerham DL, Schaid DJ, Wang L, Mushiroda T, Kubo M, Costantino JP, Vogel VG, Paik S, Goetz MP, Ames MM, Jenkins GD, Batzler A, Carlson EE, Flockhart DA, Wolmark N, Nakamura Y, Weinshilboum RM.

Cancer Discov. 2013 Jul;3(7):812-25. doi: 10.1158/2159-8290.CD-13-0038. Epub 2013 Jun 13.

49.

Synthesis of mixed (E,Z)-, (E)-, and (Z)-norendoxifen with dual aromatase inhibitory and estrogen receptor modulatory activities.

Lv W, Liu J, Lu D, Flockhart DA, Cushman M.

J Med Chem. 2013 Jun 13;56(11):4611-8. doi: 10.1021/jm400364h. Epub 2013 Jun 3.

50.

Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype dependent.

Michaud V, Kreutz Y, Skaar T, Ogburn E, Thong N, Flockhart DA, Desta Z.

Pharmacogenomics J. 2014 Apr;14(2):151-9. doi: 10.1038/tpj.2013.17. Epub 2013 Apr 30.

Supplemental Content

Loading ...
Support Center